崔富强

1. Fuqiang Cui#, Sarah Blach, Casimir Manzengo Mingiedi, Monica Alonso Gonzalez, Ahmed Sabry Alaama, Antons Mozalevskis, Nicole Séguy, Bharat Bhushan Rewari, Polin-Chan, Linh-vi Le, Niklas Luhmann, Philippa Easterbrook, Mae Dirac, Catherine de Martel, Shevanthi Nayagam, Timothy B Hallett, Peter Vickerman, Homie Razavi, Olufunmiayo Lesi , Daniel Low-beer*. Global reporting of Hepatitis B and C–progress and gaps towards elimination, The Lancet Gastroenterology & Hepatology, February 07, 2023 DOI:https://doi.org/10.1016/S2468-1253(22)00386-7 .

2. Zhou Y#, Zhao LL#, Chen J#, Zhang WX, Zhao SY, Wang C, Du J, Wei TT, Liu YQ, Lu QB*, Liu M*, Cui F*. Effects of breakthrough infections on clinical characteristics and outcomes among patients with Japanese encephalitis. J Infect. 2023 Oct;87(4):350-353. doi: 10.1016/j.jinf.2023.07.012. Epub 2023 Jul 24. PMID: 37495190.

3. Zhang SH#, Wang C#, Liu B#, Lu Q#… Cui F*. Cost-effectiveness of expanded antiviral treatment for chronic hepatitis B virus infection in China: an economic evaluation. The Lancet Regional Health -Western Pacific,2023: 100738.3.

4. Lu Q-B, Cui F*. Preventing mother-to-child transmission of HBV. Lancet Infect Dis 2022, https://doi.org/10.1016/S1473-3099(22)00206-7.

5. Chao Wang#, Bei Liu#, Sihui Zhang, Ninghua Huang, Tianshuo Zhao, Qing‐Bin Lu, Fuqiang Cui*. Differences in incidence and fatality of COVID‐19 by SARS‐CoV‐2 Omicron variant versus Delta variant in relation to vaccine coverage: A world‐wide review. J Med Virol, 29 November 2022 https://doi.org/10.1002/jmv.28358.

6. Ninghua Huang#, Chao Wang#, Bingfeng Han, Tianshuo Zhao, Bei Liu, Linyi Chen, Mingzhu Xie, Hui Zheng, Sihui Zhang, Yu Wang, Du Juan, YaQiong Liu, QingBin Lu, Fuqiang Cui*. Change in willingness to COVID‐19 vaccination in China: Two online surveys during the pandemic. J Med Virol. 2022;94:5271–5278.   

7. Wang Chao, Cui Fuqiang*. Expanded screening for chronic hepatitis B virus infection in China. Lancet GH, 2021(10)e278.

8. Zheng Hui#, Shevanthi Nayagam#, Polin Chan, Wang Fuzhen, Mark Thursz, Yin Zundong, Miao Ning, Sun Xiaojin, Fuqiang Cui*, Zhang Guomind & Timothy B Hallett. Progress towards elimination of mother-to-child transmission of hepatitis B virus infection in China: a modelling analysis. Bull World Health Organ 2020;98: doi: http://dx.doi.org/10.2471/BLT.19.248146.  

9 Cui F. Strategies to increase timely uptake of hepatitis B vaccine birth dose. Lancet Glob Health. 2020 Jul;8(7): e869-e870.7.

10. Cui F#, Shen L#, Li L#, et al. Prevention of Chronic Hepatitis B after 3 Decades of Escalating Vaccination Policy, China. Emerging Infectious Diseases, 2017, 23(5):765-772.

主要论著和技术文件

1. 主编《疫苗上市后临床研究与评价》，2020，北京大学医学出版社。

2. 主编《卫生微生物学教程》，2020，北京大学医学出版社。

3. 主编 《呼吸道合孢病毒感染》，科学出版社，2018年。

4. 主译《公共卫生实践中的流行病学》，2018，人民卫生出版社。

5. 参与《乙型病毒性肝炎诊断标准-WS 299-2008》制定。

6. 参与《流行性脑脊髓膜炎诊断标准-WS-295-2019》制定。

7. 参与起草了WHO Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022-2030(2021) 战略规划。

8. 参与制定WHO“Guidance for country validation of viral hepatitis elimination and path to elimination: technical report. Geneva: World Health Organization; 2023”;“Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact, 2022; “Interim guidance for country validation of viral hepatitis elimination. Geneva: World Health Organization; 2021”; “Prevention of mother-to-child transmission of hepatitis B virus (HBV): guidelines on antiviral prophylaxis in pregnancy, World Health Organization 2020”和“Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection” 5项国际标准和指南的制定。

9. 参与制定参与WHO “Technical Consideration and case definitions to improve surveillance for viral hepatitis 2016”, “Standard operating procedures for enhanced reporting of cases of acute hepatitis”, “Digital adaptation kit for HIV: operational requirements for implementing, WHO recommendations in digital systems, 2022”等技术指南和“Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. Accountability for the global health sector strategies 2016–2021: actions for impact. Geneva: World Health Organization; 2021”，“Accelerating access to hepatitis C diagnostics and treatment: overcoming barriers in low- and middle-income countries. Global progress report 2020. Geneva: World Health Organization”技术报告的撰写。

10. 参与《慢性乙型肝炎防治指南（2022 年版）》制定，中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南（2022 年版）.中华肝脏病杂志, 2022, 30(12): 1309-1331. DOI: 10.3760/cma.j.cn501113-20221224-00607.

11. 参与《丙型肝炎防治指南（2022 年版）》制定，中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南（2022 年版）. 中华肝脏病杂志, 2022, 30(12): 1332-1348. DOI: 10.3760/cma.j.cn501113-20221220-00605.